A1: no patient specific details have been provided.Therefore, the patient initials reflect the w.L.Gore internal case number.H3: code "other" was selected as the medical device remains implanted.Return not possible.H6: a review of the manufacturing records for the device could not be performed as a valid lot number was not provided.H6: code d12: according to the gore® cardioform septal occluder instructions for use (ifu), adverse events that may occur and/or require intervention include, but are not limited to: arrhythmia, such as atrial fibrillation or flutter, requiring treatment.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
The following was reported to gore: on (b)(6) 2024, a patient underwent treatment to close a 5.8 mm stop-flow balloon sized patent foramen ovale using 25 mm gore® cardioform septal occluder.The occluder was implanted under intracardiac echocardiography guiding.After removing a sheath and at the time of closure, an atrial fibrillation was confirmed.A transthoracic echocardiography revealed that the position of the occluder was no issue and the patient was discharged from the catheterization room.The patient tolerated the procedure.On unknown date, in 2024, antiarrhythmic medication was administered.The symptoms disappeared the next day.An mri did not reveal any cerebral infarction.The physician stated that during the procedure the patient was experiencing tachycardia.It was not certain when this happened.
|